

SOUTH JERSEY MEDICAL REPORT™



Clinical Trials More than 450 clinical trials, including national trials, are currently underway at Cooper University Health Care, addressing a wide range of the latest pharmacologic, surgical, and device-related therapeutic options. Cooper's robust research program offers clinicians and their patients access to some of the most novel therapies and innovative trials in the region.

The following list represents some of the clinical trials currently enrolling patients at Cooper.

ISSUE 17 – 2020

Study Area	Principal Investigator (PI)	Contact Info	Study Type	Study Description	Main Inclusion Criteria
Anesthesia	Kelly A. Bolkus, DO	Brian M. 856.968.7333	Treatment	Evaluate regional vs. general anesthesia for hip fracture surgery.	<ol style="list-style-type: none"> 1. Age ≥ 50 years. 2. Eligible to receive either spinal block or GA.
Anesthesia	Kingsuk Ganguly, MD	Brian M. 856.968.7333	Drug Study	Single blind evaluation of exparel vs. bupivacaine in robotic thoracic surgery.	<ol style="list-style-type: none"> 1. Age ≥ 18 years. 2. Having robotic wedge resection or lobectomy. 3. Weight 155 lbs. and above.
Anesthesia	Angelo A. Andonakakis, DO	Brian M. 856.968.7333	Device Study	This study seeks to determine if the depth of Propofol Sedation in Gastrointestinal Endoscopy Assessed by SedLine® Brain Function Monitoring Influence the Incidence of Post-Operative Delirium and Post-Operative Cognitive Dysfunction.	<ol style="list-style-type: none"> 1. Age 65 and up. 2. BMI less than 40. 3. Not taking benzodiazepine medications.
Cardiology Arrhythmia	Andrea M. Russo, MD	Claire F. BEEPER: 856.253.2361 Julie F. 856.669.8847	Treatment Study	Medication study for the reduction of thrombo-embolism in patients with device-detected sub-clinical atrial fibrillation.	<ol style="list-style-type: none"> 1. Device detected episode of SCAF ≥ 6 mins but < 24 hours. 2. Must have at least one Stroke Risk Factor.
Cardiology Arrhythmia/ Implantable Defibrillator	Andrea M. Russo, MD	Claire F. BEEPER: 856.253.2361 Julie F. 856.669.8847	Device Education Study	Patient education study about an implantable cardioverter defibrillator device (ICD) for prevention of Sudden Cardiac Death (SCD) and what kind of information is helpful to patients in making treatment decisions with their doctors.	<ol style="list-style-type: none"> 1. Age > 21. 2. Eligible for an implantable cardioverter defibrillator (ICD) for the primary prevention of sudden cardiac death. 3. Non-hospitalized patients with ejection fraction ≤ 35%.
Cardiology Pacemaker or Defibrillator	John A. Andriulli, DO	Claire F. BEEPER: 856.253.2361 Julie F. 856.669.8847	Treatment Study	Comparison of antibiotic treatment options for patients undergoing cardiac device implants (pacemakers/ defibrillators).	<ol style="list-style-type: none"> 1. Age > 17. 2. Eligible for a pacemaker or defibrillator implant. 3. Greater than one risk factor associated with increased risk of infection.
Ob/Gyn	Meena Khandelwal, MD	Elena S. 856.968.7547	Prospective Case Control	This study aims to assess the prevalence of sleep disorder breathing in pregnant women with a singleton gestation who develop hypertensive disorder of pregnancy (HDP) compared to women without HDP.	<ol style="list-style-type: none"> 1. Patient ≥ 18 years of age. 2. Women with diagnosis of a hypertensive disorder of pregnancy. 3. Greater than 20 weeks of pregnancy.

Study Area	Principal Investigator (PI)	Contact Info	Study Type	Study Description	Main Inclusion Criteria
Ob/Gyn	Lioudmila Lipetskaia, MD	Elena S. 856.968.7547	Prospective Cohort	To implement a screening process among gynecologic oncology patients to identify symptoms of pelvic floor dysfunction and to implement an early intervention program to streamline patients' access to care for pelvic floor diseases.	<ol style="list-style-type: none"> 1. Patient ≥ 18 years of age. 2. New patients presenting for treatment of a gynecologic cancer.
Hematology/ Oncology Breast	Kamel Abou Hussein, MD	Lisa A. 856.325.6719	Drug Study	This study evaluates the efficacy and safety of Pembrolizumab as adjuvant therapy for triple receptor-negative breast cancer.	<ol style="list-style-type: none"> 1. Women or Men Age ≥ 18 years. 2. ER-, PR- and HER2-negative breast cancer. 3. Residual disease of 1cm or greater and/or positive lymph nodes after neoadjuvant chemotherapy.
Trauma Surgery Acute Kidney Injury	Ju-Lin Wang, MD	Janika S.R. 856.361.1324	Drug Study	This study evaluates treatment and outcomes for patients with sepsis associated Acute Kidney Injury (SA-AKI).	<ol style="list-style-type: none"> 1. Males or Females 18 years of age to 85 years of 2. Suspected or confirmed diagnosis of abdominal infection with planned or completed surgical (laparotomy or laparoscopy) or interventional radiologic procedures within 24 hours of evaluation by medical personnel, or surgically confirmed NSTI, requiring treatment with parenteral antibiotics.
Vascular Surgery AAA	Joseph V. Lombardi, MD	Jonelle O. 856.342.2150	Device Study	This study evaluates the safety and efficacy of a polymer and endovascular graft combination in the treatment of abdominal aortic aneurysms (AAA).	<ol style="list-style-type: none"> 1. Age > 18 years. 2. Must have an aneurysm/ulcer of the abdominal aorta.
Vascular Surgery AAA	Joseph V. Lombardi, MD	Jonelle O. 856.342.2150	Device Study	This study evaluates a thoracic branch device in the treatment of aneurysms of the aortic arch and descending thoracic aorta.	<ol style="list-style-type: none"> 1. Age > 18 years. 2. Must have an aneurysm/ulcer of the thoracic aorta.

For more information about clinical trials at Cooper, please contact:

Barbara C. • Cooper Research Institute • 401 Haddon Avenue, Room 140 • Camden, NJ 08103 • P: 856.536.1030 • F: 856.536.1039

